U.S. markets open in 2 hours 1 minute

Kuehne + Nagel International AG (KNIN.SW)

Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
281.60-0.30 (-0.11%)
As of 1:10PM CEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close281.90
Open282.20
Bid281.50 x 0
Ask281.70 x 0
Day's Range280.40 - 283.30
52 Week Range129.65 - 283.40
Volume59,146
Avg. Volume199,427
Market Cap33.675B
Beta (5Y Monthly)0.89
PE Ratio (TTM)42.86
EPS (TTM)6.57
Earnings DateApr 26, 2021
Forward Dividend & Yield4.50 (1.62%)
Ex-Dividend DateMay 06, 2021
1y Target Est150.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Kuehne + Nagel Lands Global Logistics Deal For Moderna COVID-19 Vaccine
      Benzinga

      Kuehne + Nagel Lands Global Logistics Deal For Moderna COVID-19 Vaccine

      Kuehne + Nagel will provide global warehousing and distribution for Moderna Inc.'s (NASDAQ: MRNA) new COVID-19 vaccine, the Swiss third-party logistics powerhouse said Thursday.The news follows Wednesday's approval by the European Commission for the drug to be administered on a conditional basis. The EU has ordered 160 million doses from Moderna and the first deliveries to European countries from Moderna's dedicated non-U.S. supply chain are expected to begin next week, according to the Cambridge, Massachusetts-based biotechnology company.On Friday, U.K. health authorities also granted Moderna temporary use authorization for COVID-19 vaccinations as the country contends with a huge outbreak of a more contagious variant of the virus. The U.K. government also exercised its option to purchase an additional 10 million doses of the Moderna vaccine, bringing its confirmed order to 17 million doses. Canada, Israel and the U.S. have also granted emergency use authorizations for Moderna's COVID-19 vaccine, with additional authorizations under review in Singapore and Switzerland.A vaccine developed by Pfizer Inc. (NYSE: PFE) and German partner BioNTech is already being administered in the EU, Israel, the U.K. and other countries, including the U.S.Kuehne + Nagel will support the worldwide distribution of vaccine doses from Moderna's European production sites to markets in Europe, Asia, the Middle East and Africa, as well as parts of the Americas. Moderna is relying on McKesson Corp. (NYSE: MCK) to manage vaccine distribution in the U.S.The arrangement includes distribution and warehousing of the vaccine from Kuehne + Nagel's pharma hub in Europe. Kuehne + Nagel, the second-largest third-party logistics provider in the world by gross revenue ($25.9 billion in 2019), will use its network of more than 230 facilities worldwide to distribute the vaccine via road and air. In Europe alone, the company operates its own fleet of more than 200 refrigerated trucks dedicated to pharmaceuticals. At all stages of transport and storage, the Moderna product will be maintained at the required temperature of minus 20 degrees Celsius.K+N facilities meet global quality standards for the pharmaceutical industry. Facilities that also handle air shipments are certified and audited by the International Air Transport Association for meeting stringent pharmaceutical industry standards for safe handling and efficiency of temperature-sensitive products.Robert Coyle, senior vice president of pharma and health care for K+N International, said in a statement that the company had taken on the "responsibility" to distribute the Moderna vaccine around the world."We have invested in our pharma and health care network and our global team of experts for decades – we are ready now, for when it matters the most," Coyle said.K+N's clinical trial logistics subsidiary, QuickSTAT, has also provided supply logistics for Moderna's phase two and three clinical trials in the U.S.Kuehne + Nagel has also signed partnerships with authorities in several countries for local storage and last-mile distribution, including Germany's most populous state, North Rhine-Westphalia.Last year, K+N opened two pharmaceutical and health care hubs at the Brussels and Johannesburg airports for the distribution of vaccines and other products.DHL Express flightsIn related news, DHL Express said it has operated more than 50 flights since Christmas transporting COVID-19 vaccines within Europe. Countries that received first batches include Austria, Bulgaria, Croatia, Greece, Finland, Italy, Lithuania, Norway, Romania and Sweden. The express carrier said Italy, Lithuania, Norway and Romania also received second batches through its network.Besides Europe, DHL Express has also served vaccine batches to Bahrain, Chile, Costa Rica, Israel, Mexico, Oman and Singapore.Click here for more FreightWaves and American Shipper stories by Eric Kulisch.RELATED NEWS:Russia ships Sputnik vaccine to Argentina on passenger jetEmirates delivers first COVID-19 vaccines to UAEFedEx begins distributing Moderna vaccine in CanadaFirst COVID-19 vaccine shipment lands in CanadaDHL to deliver Pfizer/BioNTech vaccine in GermanyAirlines, logistics companies ramp up global vaccine deliveriesSee more from Benzinga * Click here for options trades from Benzinga * Consumer Economy To Be "A Tale of Two Halves" * Freight Bull Market Rages On In The New Year(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Reuters

      RPT-Moderna vaccine to criss-cross continent before Europeans get shots

      Moderna Inc's COVID-19 vaccine, fresh off European approval on Wednesday, must make a long, continent-crossing journey from the Swiss Alps to Spain, France and Belgium before final delivery to the EU's 27 countries. With few of its own factories, U.S.-based Moderna is reliant on partners -- big contract manufacturers, long-haul truckers, even military recruits enlisted to guard vaccines in secret warehouses -- to get shots to more than 400 million Europeans desperate for pandemic relief.

    • Reuters

      Moderna vaccine to criss-cross continent before Europeans get shots

      Moderna Inc's COVID-19 vaccine, fresh off European approval on Wednesday, must make a long, continent-crossing journey from the Swiss Alps to Spain, France and Belgium before final delivery to the EU's 27 countries. With few of its own factories, U.S.-based Moderna is reliant on partners -- big contract manufacturers, long-haul truckers, even military recruits enlisted to guard vaccines in secret warehouses -- to get shots to more than 400 million Europeans desperate for pandemic relief.